ESTABLISHEDSCIENCEscience-backed 90%

Advancing Psychedelic And Novel Therapeutics

This trend is no longer actively tracked on the public board (it faded or fell below the quality bar). The page is kept so earlier links stay live — the history below shows how it played out.
Quality 65/10060 signals10 source typessince 2026-01-27

What is this

This trend revolves around advancing psychedelic and novel therapeutics, with a strong focus on clinical trials for compounds such as psilocybin and esketamine. It gathers data from various clinical phases indicating a concerted effort to address treatment-resistant mental health and other conditions through unconventional therapies.

Why it matters

Mental health disorders are on the rise and traditional treatments often fall short, necessitating innovative solutions. Regulatory shifts and increasing societal acceptance of psychedelics have catalyzed transformative research in this space.

Investment angle

Investors can explore opportunities in biotech companies like COMPASS Pathways, MindMed, and other startups dedicated to psychedelic research. Additionally, venture capital funds and ETFs focused on novel therapeutics offer exposure to the broader sector of mental health innovation.

Sovenyr read

A promising high-risk, high-reward sector for portfolios with a taste for innovative biotech; strong buy for risk-tolerant investors. Investability: 8/10.

History

Flagged 2026-01-27 · Status ESTABLISHED (since 2026-03-15) · last active 2026-08-13
2026-03-13signals (cumulative): 13 → 602026-08-13
Y = cumulative signals, X = time. A steep climb means the cluster is actively growing; a flat or abruptly-ending line means momentum is gone.
datesignalsnewsubstance
2026-03-1313100%
2026-03-2524+1196%
2026-04-0625+196%
2026-04-1827+293%
2026-04-2930+387%
2026-05-1137+784%
2026-05-2439+285%
2026-06-0539+085%
2026-06-1643+486%
2026-06-2843+086%
2026-07-0946+387%
2026-07-2149+388%
2026-08-0157+889%
2026-08-1360+390%

Evidence

The 60 collected signals behind this trend — the 20 most recent, each linking to its primary source.
Read on SubstackTrack record